AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17584491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum/neonatal nevirapine added to antiretroviral prophylaxis
Number of subjects: 1350
Study 17584491 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 1350
Study 17584491 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective caesarean delivery
Number of subjects: 1350
Study 17584491 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA levels <400 copies/ml at delivery
Number of subjects: 1350
Study 17584491 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of HIV infection
Number of subjects: 1350
Study 15121722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided central venous catheterization
Number of subjects: 124
Study 15121722 — intervention group
Group type: COMPARATOR
Intervention: Traditional landmark-guided central venous catheterization
Number of subjects: 124
Study 11471097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy for an additional 6 months
Number of subjects: 46
Study 11471097 — intervention group
Group type: COMPARATOR
Intervention: Stopped use of both IFN and ribavirin
Number of subjects: 46
Study 11103847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise training (weight loss, aerobic and resistive exercise)
Number of subjects: 0
Study 11103847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study 11103847 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training
Number of subjects: 0
Study 11103847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (bodyweight loss and physical activity)
Number of subjects: 0
Study 9120160 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 123
Study 9120160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 8241852 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 125
Study 8241852 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise regimen
Number of subjects: 125
Study 8241852 — intervention group
Group type: COMPARATOR
Intervention: Placebo soft laser treatment
Number of subjects: 125
Study 2863843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 8
Study 2863843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 8
Study 2863843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 8
Study 2863843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31002955 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS intervention (6-month structured diet and exercise program)
Number of subjects: 200
Study 31002955 — intervention group
Group type: COMPARATOR
Intervention: Control (general diet and physical activity guidelines delivered in a single session)
Number of subjects: 200
Study 29894762 — intervention group
Group type: EXPERIMENTAL
Intervention: High Energy Dinner (HED)
Number of subjects: 24
Study 29894762 — intervention group
Group type: COMPARATOR
Intervention: Low Energy Dinner (LED)
Number of subjects: 24
Study 26846185 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) surgery
Number of subjects: 0
Study 26846185 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study 24503231 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy strapping of the injured finger to its neighbor noninjured finger for a week
Number of subjects: 121
Study 24503231 — intervention group
Group type: COMPARATOR
Intervention: Aluminum extension blocking orthosis for a week in 15° flexion
Number of subjects: 121
Study 21741060 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels in T2DM subjects (21.7 ± 3.5 ng/mL)
Number of subjects: 100
Study 21741060 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels in NGT subjects with insulin resistance (25.5 ± 6.5 ng/mL)
Number of subjects: 100
Study 21741060 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance association with IGFBP-1
Number of subjects: 100
Study 21741060 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus association with IGFBP-1
Number of subjects: 100
Study 21741060 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels with increasing number of metabolic abnormalities
Number of subjects: 100
Study 21741060 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 association with metabolic syndrome
Number of subjects: 100
Study 20923385 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol plus ipratropium
Number of subjects: 141
Study 20923385 — intervention group
Group type: COMPARATOR
Intervention: Levalbuterol alone
Number of subjects: 141
Study 18546895 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 1.5 microg x ml(‐1)
Number of subjects: 30
Study 18546895 — intervention group
Group type: COMPARATOR
Intervention: Propofol target concentration of 2.0 microg x ml(‐1)
Number of subjects: 30
Study 16060935 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a stroke unit (SU)
Number of subjects: 484
Study 16060935 — intervention group
Group type: COMPARATOR
Intervention: Treatment in a general medical ward (GMW)
Number of subjects: 484
Study 16060935 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian Stroke Scale (SSS) score < 30 on admission
Number of subjects: 484
Study 16060935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of PSE
Number of subjects: 484
Study 12768797 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 81
Study 10433097 — intervention group
Group type: EXPERIMENTAL
Intervention: CM cells cultured in high glucose (11 mM)
Number of subjects: 32
Study 10433097 — intervention group
Group type: EXPERIMENTAL
Intervention: CM cells cultured in low glucose (0.8 mM)
Number of subjects: 32
Study 10433097 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (27 age-matched)
Number of subjects: 32
Study 7674439 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-movement therapy
Number of subjects: 10
Study 7674439 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10
Study 2116773 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravenous methylprednisolone pulsing (steroid group)
Number of subjects: 40
Study 2116773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 40
Study 31101627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide (15 mg orally daily for 18 weeks)
Number of subjects: 154
Study 31101627 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2 IV on day 1 of weeks 1‐4 and repeated during weeks 12‐15 in responding patients)
Number of subjects: 154
Study 31101627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide
Number of subjects: 154
Study 31101627 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 154
Study 29183037 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiping plus oral nutritional supplements (ONS)
Number of subjects: 252
Study 29183037 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral care (Control)
Number of subjects: 252
Study 25584004 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 20 mg/m2 plus cisplatin 25 mg/m2 on days 1, 8, and 15, every 4 weeks
Number of subjects: 276
Study 25584004 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 60 mg/m2 on day 1, every 3 weeks
Number of subjects: 276
Study 23596781 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shuyu Pill (MSP)
Number of subjects: 100
Study 23596781 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride
Number of subjects: 100
Study 21253706 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (single dose for the first seven post-operative nights)
Number of subjects: 29
Study 21253706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gelatin capsule similar in appearance to zolpidem)
Number of subjects: 29
Study 19731779 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative relaxation training (IRT) - 12 weekly group sessions
Number of subjects: 32
Study 19731779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 18257345 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical plum-blossom needle therapy
Number of subjects: 160
Study 18257345 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide eye drops (Control)
Number of subjects: 160
Study 14724106 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin (0.4 ml subcutaneously every 12 h for 7 days 12 h after thrombolysis, n=96)
Number of subjects: 186
Study 14724106 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (100 U/kg x b.w. intravenous bolus, 1,000 U/h continuous infusion for 3 days, then subcutaneous 7500 U every 12 h for 4 days, n=90)
Number of subjects: 186
Study 14724106 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin
Number of subjects: 186
Study 14724106 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 186
Study 11759189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast (n = 83)
Number of subjects: 124
Study 11759189 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclomethasone 100 mcg three times daily (n = 41)
Number of subjects: 124
Study 11759189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 124
Study 11759189 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclomethasone
Number of subjects: 124
Study 11759189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 124
Study 9462573 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (routine coronary angiography followed by myocardial revascularization if feasible)
Number of subjects: 920
Study 9462573 — intervention group
Group type: COMPARATOR
Intervention: Early conservative strategy (noninvasive predischarge stress testing with planar thallium scintigraphy and radionuclide ventriculography)
Number of subjects: 920
Study 7992095 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alfa (IFN‐alpha)
Number of subjects: 0
Study 3377519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent film dressing (TFD [Bioclusive])
Number of subjects: 58
Study 3377519 — intervention group
Group type: COMPARATOR
Intervention: Conventional dry gauze dressing (Curity) and antibiotic ointment (Polysporin)
Number of subjects: 58
Study 31538948 — intervention group
Group type: EXPERIMENTAL
Intervention: TECCU (G_TECCU intervention group)
Number of subjects: 63
Study 31538948 — intervention group
Group type: EXPERIMENTAL
Intervention: G_NT (nurse‐assisted telephone care)
Number of subjects: 63
Study 31538948 — intervention group
Group type: COMPARATOR
Intervention: G_control (standard care)
Number of subjects: 63
Study 29145813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gist version of decision aid
Number of subjects: 1031
Study 29145813 — intervention group
Group type: COMPARATOR
Intervention: Extended version of decision aid
Number of subjects: 1031
Study 26342782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 80
Study 26342782 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 23280675 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotiv® (Hypericum perforatum Special Extract - Ze 117)
Number of subjects: 20
Study 23280675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicabate CQ Nicotine Replacement therapy (NRT)
Number of subjects: 20
Study 23280675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NRT/HP
Number of subjects: 20
Study 23280675 — intervention group
Group type: EXPERIMENTAL
Intervention: HP group
Number of subjects: 20
Study 23280675 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT group
Number of subjects: 20
Study 21593301 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin targeting postprandial glycemia
Number of subjects: 1115
Study 21593301 — intervention group
Group type: COMPARATOR
Intervention: Insulin targeting fasting/premeal glycemia
Number of subjects: 1115
Study 18283509 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (2,940 nm) with variable pulse durations (1 ms to 2 ms) and energy densities (800 mJ/cm(2) to 1,400 mJ/cm(2)), 4 to 8 passes, single session
Number of subjects: 30
Study 16488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with full-dose tenecteplase (n=829)
Number of subjects: 1667
Study 16488800 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (n=838)
Number of subjects: 1667
Study 16488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI with full-dose tenecteplase
Number of subjects: 1667
Study 16488800 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 1667
Study 14504416 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg initial dose, mean dosage 800 +/- 397 mg, range 300-1200 mg)
Number of subjects: 16
Study 14504416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.5 mg initial dose, mean dosage 0.78 +/- 0.47 mg, range 0.25-1.50 mg)
Number of subjects: 16
Study 10881481 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic lung biopsy
Number of subjects: 61
Study 10881481 — intervention group
Group type: COMPARATOR
Intervention: Open lung biopsy
Number of subjects: 61
Study 9165958 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1 given 30 min pre-operatively
Number of subjects: 85
Study 9165958 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine 2 mg.kg‐1 given 90 min pre-operatively
Number of subjects: 85
Study 9165958 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 85
Study 9165958 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 85
Study 9165958 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine
Number of subjects: 85
Study 9165958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9165958 — intervention group
Group type: COMPARATOR
Intervention: Midazolam, Trimeprazine, Placebo
Number of subjects: 85
Study 8238827 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fresh gas flow from 40 to 120 ml.kg‐1 x min‐1 (Group 1)
Number of subjects: 45
Study 8238827 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fresh gas flow and charcoal filter (Group 2)
Number of subjects: 45
Study 8238827 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fresh gas flow and change of anaesthetic machine (Group 3)
Number of subjects: 45
Study 3634793 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational pelvic examination
Number of subjects: 213
Study 3634793 — intervention group
Group type: COMPARATOR
Intervention: Traditional pelvic examination
Number of subjects: 213
Study 30400971 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine supported progressive resistance training (n = 10)
Number of subjects: 20
Study 30400971 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 20
Study 28108224 — intervention group
Group type: EXPERIMENTAL
Intervention: Elcatonin monotherapy (20 units weekly)
Number of subjects: 51
Study 28108224 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronic acid hydrate monotherapy (1 mg daily)
Number of subjects: 51
Study 28108224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (elcatonin and minodronic acid hydrate)
Number of subjects: 51
Study 26054049 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% portion size reduction
Number of subjects: 33
Study 26054049 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% portion size reduction
Number of subjects: 33
Study 26054049 — intervention group
Group type: COMPARATOR
Intervention: Control (no portion size reduction)
Number of subjects: 33
Study 23212730 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-focused psychotherapy approaches
Number of subjects: 193
Study 21188563 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids + rituximab
Number of subjects: 62
Study 21188563 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 62
Study 18054305 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension (average 30% reduction in systolic tension) during the first operative phase; n=23
Number of subjects: 51
Study 18054305 — intervention group
Group type: COMPARATOR
Intervention: Normotension maintained during the entire procedure; n=28
Number of subjects: 51
Study 18054305 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension
Number of subjects: 51
Study 18054305 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with nitroprusside
Number of subjects: 51
Study 16825268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day bovine colostrum protein concentrate (CPC)
Number of subjects: 29
Study 16825268 — intervention group
Group type: COMPARATOR
Intervention: 10 g/day whey protein (placebo)
Number of subjects: 29
Study 15126541 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 37
Study 15126541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 11422471 — intervention group
Group type: EXPERIMENTAL
Intervention: BOAM (Colloidal bismuth subcitrate, omeprazole, amoxycillin, metronidazole)
Number of subjects: 34
Study 11422471 — intervention group
Group type: COMPARATOR
Intervention: BAM (Colloidal bismuth subcitrate, amoxycillin, metronidazole)
Number of subjects: 34
Study 11422471 — intervention group
Group type: COMPARATOR
Intervention: OAM (Omeprazole, amoxycillin, metronidazole)
Number of subjects: 34
Study 11422471 — intervention group
Group type: COMPARATOR
Intervention: AM (Placebo bismuth, amoxycillin, metronidazole)
Number of subjects: 34
Study 9471633 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective psychoses and depressive neuroses
Number of subjects: 0
Study 9471633 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients suffering from depression or physical illness
Number of subjects: 0
Study 8216665 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lignocaine 4 mg/kg (group A)
Number of subjects: 60
Study 8216665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 10 mg/kg (group B)
Number of subjects: 60
Study 8216665 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (group C)
Number of subjects: 60
Study 3619708 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 10
Study 3619708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30145099 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (neonatal schedule)
Number of subjects: 1649
Study 30145099 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (infant schedule)
Number of subjects: 1649
Study 30145099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1649
Study 29906071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew apple juice (240 mg/day)
Number of subjects: 45
Study 29906071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew apple juice (120 mg/day)
Number of subjects: 45
Study 29906071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25531294 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell deadlift training for 10 weeks
Number of subjects: 24
Study 25531294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 22766450 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Stimulation (TS)
Number of subjects: 30
Study 22766450 — intervention group
Group type: COMPARATOR
Intervention: Control (3 consultations per week for 6 weeks)
Number of subjects: 30
Study 21116892 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-BHA (Minimally Invasive Surgery - Bipolar Hemiarthroplasty)
Number of subjects: 83
Study 21116892 — intervention group
Group type: COMPARATOR
Intervention: Conventional BHA
Number of subjects: 83
Study 18928091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs for supplementing Shen, orally administered three days before and after ESWL
Number of subjects: 60
Study 18928091 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet and hydration)
Number of subjects: 60
Study 15946284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy using ice cubes before and during chemotherapy infusions.
Number of subjects: 60
Study 11677298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile‐kinesthetic stimulation (structured baby massage)
Number of subjects: 48
Study 11677298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tactile‐kinesthetic stimulation)
Number of subjects: 48
Study 9627740 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐vitamin E (1600 IU per day)
Number of subjects: 40
Study 9627740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8154822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute perioperative normovolaemic haemodilution with retransfusion of autologous blood (900 ml taken preoperatively, replaced with 1000 ml of gelatin solution)
Number of subjects: 40
Study 8154822 — intervention group
Group type: COMPARATOR
Intervention: No blood taken (control group)
Number of subjects: 40
Study 8154822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups allowed a fall in haematocrit (Hct) to 0.25 before transfusion started
Number of subjects: 40
Study 2484360 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidant cocktail (betacarotene, vitamins B6, C, E, zinc, selenium)
Number of subjects: 45
Study 2484360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2484360 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidant cocktail
Number of subjects: 45
Study 2484360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation (2 mg daily)
Number of subjects: 45
Study 29211857 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued antiarrhythmic drug treatment (ADT ON)
Number of subjects: 153
Study 29211857 — intervention group
Group type: COMPARATOR
Intervention: Discontinued antiarrhythmic drug treatment (ADT OFF)
Number of subjects: 153